Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

• Published in: ESMO open Vol. 8; no. 2; p. 100884
• Main Authors: Hecht, J.R., Raman, S.S., Chan, A., Kalinsky, K., Baurain, J.-F., Jimenez, M.M., Garcia, M.M., Berger, M.D., Lauer, U.M., Khattak, A., Carrato, A., Zhang, Y., Liu, K., Cha, E., Keegan, A., Bhatta, S., Strassburg, C.P., Roohullah, A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2023; Elsevier
• Subjects: Adult; breast neoplasms; Cohort Studies; Colorectal Neoplasms - therapy; drug therapy combination; gastrointestinal neoplasms; Humans; Liver Neoplasms - drug therapy; Melanoma - therapy; Oncolytic Virotherapy - adverse effects; Original Research; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - etiology; viral immunotherapy; virotherapy; viral immunotherapy; gastrointestinal neoplasms; virotherapy; drug therapy combination; breast neoplasms
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2023.100884

Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation. T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than either agent alone. Safety/efficacy of the combination was explored in patients with triple negative breast cancer (TNBC) or colorectal cancer (CRC) with liver metastases. In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU/ml; ≤4 ml) was administered into hepatic lesions via image-guided injection every 21 (±3) days. Atezolizumab 1200 mg was given on day 1 and every 21 (±3) days thereafter. Treatment continued until patients experienced dose-limiting toxicity (DLT), had complete response, progressive disease, needed alternative anticancer treatment, or withdrew due to an adverse event (AE). The primary endpoint was DLT incidence, and secondary endpoints included efficacy and AEs. Between 19 March 2018 and 6 November 2020, 11 patients with TNBC were enrolled (safety analysis set: n = 10); between 19 March 2018 and 16 October 2019, 25 patients with CRC were enrolled (safety analysis set: n = 24). For the 5 patients in the TNBC DLT analysis set, no patient had DLT; for the 18 patients in the CRC DLT analysis set, 3 (17%) had DLT, all serious AEs. AEs were reported by 9 (90%) TNBC and 23 (96%) CRC patients, the majority with grade ≥3 [TNBC, 7 (70%); CRC, 13 (54%)], and 1 was fatal [CRC, 1 (4%)]. Evidence of efficacy was limited. Overall response rate was 10% (95% confidence interval 0.3-44.5) for TNBC; one (10%) patient had a partial response. For CRC, no patients had a response; 14 (58%) were unassessable. The safety profile reflected known risks with T-VEC including risks of intrahepatic injection; no unexpected safety findings from addition of atezolizumab to T-VEC were observed. Limited evidence of antitumor activity was observed. •Safety/efficacy of T-VEC + atezolizumab was explored in patients with triple negative breast cancer or colorectal cancer.•Limited evidence of antitumor activity was observed from the combination of atezolizumab and T-VEC injected into the liver.•The safety profile reflected known risks with T-VEC, with no unexpected findings from the addition of atezolizumab.